[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507153":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":31,"responsibleParty":47,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":69,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Colorectal Cancer",null,"Colorectal cancer patients with advanced or recurrent tumors",[13],"Other: Molecular Profiling & drug testing in tumor organoids and PDXs",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Molecular Profiling & drug testing in tumor organoids and PDXs","Molecular profiling of native tumor will be performed and analyzed by using a self-designed panel. Tumor organoids will be cultured from fresh tumor tissues and patient-derived xenografts model will be established using the tumor organoids. Drugs will be tested in the two models. And the recommendation will be communicated to the clinicians.",[9],[20],{"name":21,"affiliation":5,"role":22},"Zheng Wang, MD\u002FPhD","STUDY_CHAIR",[24,28],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+86 2785726612","zhengwang@hust.edu.cn",{"name":29,"role":25,"phone":26,"phoneExt":10,"email":30},"Luming Xu","lumingxu@hust.edu.cn",[32],{"facility":33,"status":10,"city":34,"state":35,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Wuhan Union Hospital, China","Wuhan","Hubei","China","CN",{"type":39,"coordinates":40},"Point",[41,42],114.26667,30.58333,{"lat":42,"lon":41},[45],{"name":21,"role":25,"phone":46,"phoneExt":10,"email":10},"+86278576612",{"type":48,"investigatorFullName":21,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Study chair, Clinical Professor","100507153","molecular-study-and-precision-medicine-for-colorectal-cancer-100507153",false,"NCT05883683","Molecular Study and Precision Medicine for Colorectal Cancer","Precision Medicine for Advanced or Recurrent Colorectal Cancer Directed by High-throughput Sequencing and Tumor Organoids Model","MSPM","Inclusion Criteria:\n\n* Male or female patients, age 18 to 75 years old\n* Patients with a documented (histologically- or cytologically-proven) advanced or recurrent colorectal cancer\n* Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 1 and a life expectancy of at least 3 months\n* Patients, both male and female, who are either not of childbearing potential or who agree to use a medically effective method of contraception during the study and for 3 months after the last dose of study drug.\n* Patients with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.\n\nExclusion Criteria:\n\n* Patients with any other life-threatening illness, significant organ system dysfunction, or clinically significant laboratory abnormality, which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the study drug\n* Patients with abnormal coagulation function, bleeding tendency, or receiving thrombolytic or anticoagulant therapy\n* Patients with any other serious\u002Factive\u002Funcontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever \\> 38ºC within 2 weeks prior to first study drug administration.\n* Patients with a history of human immunodeficiency virus (HIV) or any other immunodeficiency disease.\n* Patients who are currently using certain drugs that are not permitted\n* Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and\u002For completion of the necessary studies\n* Patients with the inability, in the opinion of the Investigator, to comply with the protocol requirements","ALL","18 Years","75 Years",{"count":62,"type":63},100,"ESTIMATED","OBSERVATIONAL","Researchers collect specimens from advanced or recurrent colorectal cancer (CRC) patients to conduct molecular profiling and establish tumor organoids (PDOs)\u002F patient-derived xenografts (PDXs). The aim of this study is to identify clinical actionable targets and predict in vivo response of the tumor to targeted drugs by using PDOs\u002F PDXs. And the above-mentioned studies will provide the patients with potential personalized cancer treatment options.",[67,68],"Advanced Colorectal Carcinoma","Recurrent Colorectal Carcinoma","NOT_YET_RECRUITING","2024-07-22",{"date":72,"type":73},"2024-07-24","ACTUAL",{"date":75,"type":63},"2024-10-01",{"date":77,"type":63},"2026-07-01",{"name":5,"class":6},1]